Replies to post #55011 on Biotech Values

[microcapfun]

>>Even given the small subgroup and the Halabi nomogram estimated accuracy of 69%, a suggested benefit in median survival of over 20 months is impressive.<<

Check your math, rancherho!


>>IMO, the sometimes expressed theory that only the healthier patients would select docetaxel afer Provenge or GVAX is dubious, especially where Drs. Petrylak and Small both use Halabi as a standard reference.<<

Halabi's nomogram was essentially pre-taxotere.


>>At the end of the study 13 of 34 patients in the radiologic group received subsequent chemotherapy (taxane in 9/13); their median survival was more than 35.2 months (95%CI, 29, 44). The median survival of the non-chemotherapy treated patients was 17.2 months (95% CI, 9, 32).<<

Point made, but note the size of them thar error bars!

>>17.2 months (95% CI, 9, 32).<<

Fold the statistical errors in with the self selection ("dead men don't take chemo") and it would seem the jury is at least not unanimous.

micro